HIV Drugs Market to Reach US$ 22.5 Billion by 2024 | CAGR of 2.5%

Global HIV Drugs Market Research Report and Forecast

Report Edition: 2019 © 2019 IMARC All Rights Reserved

Copyright © IMARC Service Pvt Ltd. All Rights Reserved

About IMARC Group

Report Description

The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Report Description and Highlights

Report Description Global HIV Drugs Market Overview:

IMARC Group’s latest report, entitled “HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, finds that the global HIV drugs market exceeded tha value of US$ 24.7 billion in 2018. HIV, also known as human immunodeficiency virus, damages the immune system by destroying the white blood cells (WBCs) that fight against the infections. HIV drugs are used to make the immune system strong enough to resist certain infection and related cancers. At present, highly active antiretroviral therapy (HAART) is the most commonly prescribed treatment. It has different combinations of one protease inhibitor and other drugs. These combinations help in enhancing the amount of virus in the blood.

Malic Acid Market Trends According to the estimates by the World Health Organization, around 36 million people became newly infected at the end of 2017. This growing patient population has led to increased demand for HIV drugs. Further, various initiatives and campaigns undertaken by government have created awareness among the masses about the advancements and discoveries of modern medicines for HIV treatment.

These awareness campaigns have helped in early detection of the disease, enabling patients to start antiretroviral therapy in the initial stage of the infection.

Report Description and Highlights

157.3 146.7 152.0 141.4 136.1 125.5 130.8

160 140 120 100 80 60 40 20 0

120.2 2011

2012

2013

2014

2015

2016

2017

2018

In Million US$

in Million US$

Report Description

180 160 140 120 100 80 60 40 20 0

160.0 2019

175.9

181.2

186.5

165.3

170.6

2020

2021

2022

2023

2024

Due to this, the patients usually refuse to visit physicians and undergo disease diagnosis. Along with this, HIV treatment has numerous side effects, so they stop treatment. Owing to these factors, the market in anticipated to reach a value of US$ 22.5 Billion by 2024, declining ate a CAGR of 2.5% during the forecast period (2019-2024).

Report Description and Highlights

Report Description

Apart from this many international organizations are supporting research institutes by providing funds for R&D activities to develop innovative, affordable, safe, and efficient medicines for effectives therapeutic solutions.

However, the cost of antiretroviral drugs is relatively high and patients without healthcare coverage find it extremely difficult to pay. Besides this, individuals suffering from the infection are perceived negatively or face discrimination in society due to false opinion or misconception about it.

Key Market Segmentation: Market Segmentation by Drug Class • • • • •

Nucleoside Reverse Transcriptase Inhibitors Multi-Class Combination Products Protease Inhibitors HIV Integrase strand Transfer Inhibitors Non- Nucleoside Reverse Transcriptase Inhibitors

Based on drugs class, nucleoside reverse transcriptase inhibitors represent the most prominent class.

Report Description and Highlights

Report Description

These inhibitors are followed by multi-class combinations products, non nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors- CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.

Market Segmentation by Distribution Channel • • • •

Hospital Pharmacies Retail Pharmacies Online Pharmacies others

The market also has been segregated on the basis of distribution channels into hospital pharmacies, retail pharmacies, online pharmacies and others. Currently, these drugs are majorly distributed through hospital pharmacies.

Market Segmentation by Region • •

North America Europe

Report Description and Highlights

Report Description • • •

Asia Pacific Latin America Middle East and Africa

Region-wise, North America exhibits a clear dominance in the market. Other major regions include Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape: The competitive landscape of the market has also been examined with some of the key players.

• • • • • • •

Boehringer Ingelheim International Gmbh Merck & Co. Inc ViiV Healthcare AbbVie F. Hoffmann-La Roche Ltd. Teva Pharmaceutical industries Ltd. Bristol-Myers Squibb

Report Description and Highlights

Report Description • • • • • • •

Gilead Sciences, Inc Johnson & Johnson Cipla Limited Diichi Sankyo Emcure Hetero Drugs Mylan

For more information, click here: https://www.imarcgroup.com/hiv-drug-market

A partial List of

We are the trusted business partners to the

Clients world's leading corporates, governments, and ourPartial ClientsList of institutions

A partial List of

We are the trusted business partners to the

of Clients leading corporates, governments, and ourPartial ClientsListworld's institutions

Report Description and Highlights

Report Description

Š 2019 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

Contact Us

FOR MORE DETAILS Visit us at :

https://www.imarcgroup.com Stay With Us:

TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com